MURA Mural Oncology
- 3.230
- -0.070-2.12%
- 3.250
- +0.020+0.62%
Mural Oncology News
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to
Express News | Mural Oncology Shares Data From ARTISTRY-3 Trial Designed To Evaluate Effects Of Less Frequent Intravenous Dosing Of Nemvaleukin Alfa In Advance Of ASCO Annual Meeting
Mural Oncology Presents Clinical Data From ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural's late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally
Mural Oncology | 10-Q: Quarterly report
Express News | Mural Oncology PLC Qtrly Shr Loss $1.84
Mural Oncology 1Q Research and Development Expenses $26.9M >MURA
Mural Oncology 1Q Research and Development Expenses $26.9M >MURA
Express News | Mural Oncology PLC: Reiterates Cash Runway Projection Into 4Q 2025, With Sufficient Capital to Fund Key Clinical Readouts
Express News | Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year Combination of IL-18 binding protein resistance with additional
Express News | Mural Oncology Shares Are Trading Higher After Morgan Stanley Initiated Coverage on the Stock With an Overweight Rating and a $13 Price Target
Mural Oncology Initiated at Overweight by Morgan Stanley
Mural Oncology Initiated at Overweight by Morgan Stanley
Express News | Morgan Stanley Initiates Coverage On Mural Oncology With Overweight Rating, Announces Price Target of $13
Mural Oncology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/04/2024 186.98% Morgan Stanley → $13 Initiates Coverage On → Overweight
Mural Oncology's Buy Rating: Financial Stability and Promising Drug Candidate Propel Growth Prospects
We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully
Mural Oncology Plc GAAP EPS of -$3.57
Express News | Mural Oncology Q4 EPS $(3.57) Down From $(2.91) YoY, Cash Balance of $270.9M
Mural Oncology Anticipates Reporting Lower Operating Expenses in the Quarters Going Forward >MURA
Mural Oncology Anticipates Reporting Lower Operating Expenses in the Quarters Going Forward >MURA
Mural Oncology: Cash Resources Expected to Fund Ops Into 4Q 2025 >MURA
Mural Oncology: Cash Resources Expected to Fund Ops Into 4Q 2025 >MURA
Analysis
Price Target
No Data
